Furthermore, the sub-protocol C of the previously mentioned master protocol HEM-iSMART will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of ruxolitinib with venetoclax in combination with dexamethasone, cyclophosphamide, and cytarabine in children and AYAs with R/R ALL with alterations in the IL-7R and/or JAK-STAT signaling pathways [50]. Here, SOAT1 is linked to acute lymphoblastic leukemia.